- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer | Clinical
FDA Okays Guardant360 Test as CDx for Elacestrant in ESR1-mutated Breast Cancer
January 30, 2023
The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.
Update of DESTINY-Breast03 Emphasizes Safety of Trastuzumab Deruxtecan in mBC
January 30, 2023
Erika P. Hamilton, MD, discusses the updated safety analysis of the DESTINY-Breast03 trial and the patients who were enrolled in the study.
Next Steps for Trastuzumab Emtansine After the KAMILLA Trial
January 23, 2023
Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Addressing Patient Subgroups Is a Key Topic During Breast Cancer Conference
January 20, 2023
Recent updates to clinical care for patients with ER-positive disease include the emergence of breast cancer subtypes, oral selective estrogen receptor degraders, and other oral targeted therapies.
RWD Show Survival Advantage of Frontline Letrozole Plus Palbociclib in Minorities With aBC
January 18, 2023
Adam Brufsky, MD, PhD, FACP, discusses the real-world efficacy of letrozole in combination with palbociclib as treatment of patients with estrogen receptor-positive, HER2-negative, advanced breast cancer, based on race and ethnicity.
Zotatifin With Fulvestrant and Abemaciclib Shows Favorable Activity in ER+ Breast Cancer
January 12, 2023
In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.
FDA Grants Fast Track Designation to Novel TKK1 Therapy for ER+/HER2- Advanced Breast Cancer
January 10, 2023
The investigational drug, CFI-402257, has earned the FDA’s attention for promising preclinical results, and is now under investigation in a phase 1 study.
Trial Readouts Will Enforce the Role of Trilaciclib Across Multiple Cancers in 2023
January 10, 2023
Starting with the PRESERVE 1 trial of patients with metastatic colorectal cancer, 5 pivotal trials evaluating trilaciclib will announce results in 2023.
Hurvitz Discusses Use of SERDs in Patients With Breast Cancer
December 30, 2022
During a Targeted Oncology Evolving Paradigms roundtable, Sara A. Hurvitz, MD, discussed elacestrant and other investigational agents for patients with breast cancer.
The Next-Generation Promise of ADCs and SERDs in Breast Cancer
December 28, 2022
The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer.